Premium
Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post‐Resection (Adv. Funct. Mater. 43/2022)
Author(s) -
Sun Shuo,
Gu Wei,
Wu Haisi,
Zhao Qianqian,
Qian Shiyu,
Xiao Hong,
Yang Kun,
Liu Jian,
Jin Yu,
Hu Chupeng,
Gao Ye,
Xu Huae,
Liu Hongyi,
Ji Jing,
Chen Yun
Publication year - 2022
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202270246
Subject(s) - materials science , glioblastoma , immune system , radiation therapy , cancer research , radioimmunotherapy , agonist , medicine , immunology , receptor , antibody , monoclonal antibody
Flexible Optoelectronics In article number 2205038, Huae Xu, Hongyi Liu, Jing Ji, Yun Chen, and co‐workers present an injectable, reactive oxygen species‐responsive therapeutic hydrogel (ADU‐AAV‐PD1@Gel), capable of sustained local release of soluble PD‐1 (sPD‐1) and STING agonist ADU‐S100. The ADU‐AAV‐PD1@Gel combined with radiotherapy generates a robust antitumor immune response and induces long‐term immune memory to prevent glioblastoma recurrence.